Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMAHA-004: opevesostat versus alternative abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer
2023-504957-11-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 39
01
Overview
Phase 3, randomised, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoint: Radiographic Progression-free Survival. Planned start Apr 2024; status: authorised.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-504957-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504957-11-00.